VistaGen Therapeutics has released its financial results, showing a mixed performance against Wall Street expectations. The company reported an earnings per share miss of $0.05, while total revenue for the period came in above analyst estimates.
Additional financial details, including specific revenue figures and net income metrics, were not immediately available following the announcement.
